Expression of cellular receptors determines viral tropism and limits gene delivery by viral vectors. Protein transduction domains (PTDs
Viral vectors are the most efficient means for gene delivery in mammalian cells. Adenoviruses have been widely used for gene therapy applications in vivo and in vitro, as they are able to accommodate large transgenes, can be propagated to high titers and transduce cells independently of their replicative state. However, applications for adenoviral vectors have been limited by the native tropism of the virus. Viral infection first requires efficient binding of viral particles to the plasma membrane prior to cellular uptake. In human epithelial and other permissive cells, entry of species C adenoviruses, including the currently used adenovirus types 2 and 5, depends on the presence of the coxsackievirus B adenovirus receptor (CAR) and integrin coreceptors. The CAR cytoplasmic and transmembrane domains are dispensable for viral entry, indicating that CAR functions solely as an attachment molecule (26, 45, 46) . Once the adenovirus has attached to CAR, subsequent events resulting in viral entry are mediated entirely by integrins, such as av␤3 and av␤5 (48) , a5␤1 (7) , and av␤1 (8, 27) . Although complex mechanisms are involved, the adenoviral CAR recognition and interaction represent the rate-limiting step of viral infection (15, 21, 52) . Human and murine genes for CAR have been identified, and both proteins enable adenoviral infection when corresponding constructs are transfected into nonpermissive CAR-negative tumor or primary cells (2, 3, 26, 39, 40, 46) .
In CAR-expressing cells, the receptor is abundant at tight junctions and functions primarily as an adhesion factor by dimerizing with CAR molecules on adjacent cells. CAR sequestered within tight junctions is inaccessible to adenovirus, thus limiting viral spread across epithelial surfaces (4) . In the course of adenoviral replication, fiber protein is excessively produced and secreted. Binding to CAR then results in disruption of junctional integrity, facilitating viral escape across the epithelial barrier (44) . Integrity and polarity disorders of epithelial cells by changes in the microenvironment, including early malignant transformation, lead to upregulation of CAR expression (1) . It has been described that the transmembrane and cytoplasmic domains of CAR mediate growth-inhibitory signals in tumor cells (36) . Therefore, CAR-negative cancer cells are selected in later stages of tumor progression. Reduced expression of CAR in advanced tumor stages is one of the major hurdles of adenoviral cancer gene therapy (28) .
Some proteins, including Tat (transactivator of transcription) of human immunodeficiency virus (HIV) (17, 19) , VP22 of herpes simplex virus (HSV) (13) , and antennapedia homeodomain proteins (AntPs) of Drosophila melanogaster and other species (9, 24) are taken up by mammalian cells via an un-known receptor-independent pathway. The identified domains responsible for this property were referred to as protein transduction domains (PTDs) (9, 13, 43) . Sequence analysis revealed that most PTDs are 10 to 30 amino acid residues in length and enriched in basic amino acids, e.g., arginine and lysine. PTDs have been reported to deliver therapeutic proteins (37, 53) , antisense oligonucleotides (35) , liposomes (41, 42) , and plasmid DNA (11, 23, 38) into mammalian cells. However, the therapeutic relevance of PTD-mediated cellular uptake is still controversially discussed. There is evidence that the strong cytosolic and nuclear staining of PTD-fusion proteins in target cells may be due to a fixation artifact (29) . Furthermore, intracellular translocation by PTD-fusion proteins is in some cases not efficient enough to mediate significant biologic or therapeutic effects in target cells (14, 25) .
It was described that pretreatment of adenoviral particles with short chemically synthesized oligopeptides corresponding to the PTDs of Tat or AntP improved adenoviral infection efficacy in vivo and in vitro (18) . However, high concentrations of these peptides had to be applied to obtain significant effects. In our study, PTDs were fused to the ectodomain of the CAR receptor to serve as molecular adapters between the adenoviral fiber knob protein and negatively charged surface structures. Application of these adapter molecules strongly increased the affinity of adenoviral particles to CAR-negative nonpermissive cells, allowing efficient infection. Interestingly, CAR ex -PTDs not only enabled adenoviral infection of nonpermissive tumor cells but also significantly increased the viral uptake rates in permissive tumor cells. We therefore developed recombinant molecular adapters to broaden the spectrum of adenoviral tropism to CAR-negative cells independent of their receptor expression pattern.
MATERIALS AND METHODS
Cell lines and plasmids. HepG2, Huh7, HT1080, HT29, SAOS-2, MCF-7, U2-OS, SKLU-1, H4IIE, BNL, RT101, T-36274, HeLa, KLN 205, Jurkat-T, P388D.1, RAW264.7, COS-1, and 293 cell lines were obtained from the American Type Culture Collection (Rockville, Md.). Rat ISC cells were kindly provided by K. Wewetzer (Hanover, Germany). Cells were maintained in growth medium (Dulbecco's modified Eagle's medium plus Glutamax; Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies), 100 U of penicillin/ml, and 100 g of streptomycin (Seromed)/ml at 37°C in 5% CO 2 . MCF-7 cells were additionally supplied with 5 g of insulin/ml plus 5 g of transferrin/ml and 5 ng of sodium selenite (Roche Diagnostics)/ml. DC2.4 cells were kindly provided by K. L. Rock (Worcester, Mass.). DC2.4 cells were maintained in HCM medium (10% FBS, 100 U of penicillin/ml, 100 g of streptomycin/ml, 2 mM L-glutamine, 1% MEM nonessential amino acids [Life Technologies], 10 mM HEPES, and 50 M ␤-mercaptoethanol).
The plasmid LXSN-hCAR encoding the human CAR (hCAR) was a gift from J. DeGregori (Denver, Colo.). The vector pVP22mycHis 2 was purchased from Invitrogen.
Plasmid construction. For the generation of CAR ex -VP22, a fragment coding for signal sequence and extracellular domain of the human CAR receptor (CAR ex ) (amino acids [aa]1 to 235) was generated via PCR using the plasmid LXSN-hCAR as a template. The oligonucleotides 5Ј-GTGGTACC ATG GCG CTC CTG CTG TGC TTC GTG C-3Ј (the KpnI site is in italics and the natural start codon of hCAR is in boldface type) and 5Ј-TAGCGGCCGCC TTT ATT TGA AGG AGG GAC AAC GTT TAG ACG C-3Ј were used as primers (the NotI site is in italics; bases printed in boldface are complementary to the 3Ј terminus of the hCAR extracellular domain). The resulting fragment was digested with KpnI and NotI and subcloned into the corresponding restriction sites of pVP22mycHis 2 to create an N-terminal CAR fusion protein (plasmid name, pCAR ex -VP22). The plasmids encoding fusion proteins of CAR ex and the putative cellular adhesion domains of the HIV Tat protein and AntP, an oligopeptide consisting of nine arginine residues, and an oligopeptide consisting of Gly/Ser/ Thr residues as a competitor were generated with synthetic oligonucleotides. All oligonucleotides described below were hybridized with a respective antisense strand, digested with NotI/XbaI, and inserted into the corresponding sites of pCAR ex -VP22, thereby replacing the VP22 coding fragment. All of the following oligonucleotides contained a sequence for additional glycine and serine residues for spacing the cellular adhesion domain from CAR ex ; the NotI and XbaI sites are given in italics. For cloning of pCAR ex -Tat [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , the oligonucleotide 5Ј AAAGC GGC CGC GGA GGA GGA AGT GGA GGA GGA GGA GGC AGG AAG AAG CGG AGA CAG CGA CGA AGA GGT CTA GAAA-3Ј (coding for aa 48 to 57 of the HIV-Tat protein,; sequence GRKKRRQRRR) was used. The insertion of the sequence 5ЈAAAGC GGC CGC GGA GGA GGA AGT GGA GGA GGA GGA CGT CGC CGA CGG AGA AGG AGA CGT AGA GGT CTA GAAA-3Ј (the coding sequence for RRRRRRRRR is in boldface type) resulted in the plasmid pCAR ex -9xArg. The fusion of CAR ex with AntP was achieved by inserting the oligonucleotide 5ЈAAGC GGC CGC GGA GGA GGA GGA AGA CAG ATC AAA ATA TGG TTC CAA AAC CGG CGC ATG AAA TGG AAG AAA GGT CTA GAAA-3Ј (encoding RQIKIWFQNRRMKWKK, representing aa 62 to 77 of Euprymna scolopes AntP), therefore resulting in the plasmid pCAR ex -AntP 62-77 . For the generation of a CAR ex version lacking a functional cellular adhesion domain, the Tat 48-57 coding sequence of pCAR ex -Tat [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] was replaced by the sequence 5Ј-AAAGCGGCCGC GGA GGA GGA AGT GGA TCT GGA TCT GGT TCT GGA TCA ACT GGA TCA ACA TCT GGA GGTCTAGAAA-3Ј, encoding Gly/Ser/Thr residues.
A Tat [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] control peptide able to be secreted into the extracellular space was generated by deleting large internal parts of the CAR ex domain in CAR ex -Tat, thereby leaving the signal sequence of CAR for proper secretion. pCAR exTat [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] was digested with EcoRV and NotI (Klenow fill in), and the vector fragment was then religated in-frame with the linker d(pCGGGATCCCG) (NEB), resulting in the plasmid pCAR 1-58 -Tat [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . For the expression of VP22 protein, the vector pVP22mycHis 2 (Invitrogen) was applied.
All plasmids were sequenced and tested for expression of CAR fusion proteins and control proteins by Western blot analysis. A mouse anti-myc antibody (Invitrogen) was used as a primary antibody. Plasmids were prepared with the EndoFree Maxi kit (QIAGEN).
Construction and preparation of recombinant adenovirus. For the production of larger quantities of purified CAR ex -VP22 and CAR ex -Tat proteins, PTDexpressing adenoviruses were constructed. AdCAR ex -VP22 was generated using an in vitro ligation method (Adeno-X expression system; BD Biosciences). pHM3/pBK-CMV, a modified version of pHM3 which contained the eukaryotic expression cassette of pBK-CMV (Stratagene), was used as a shuttle vector. The cDNA fragment was excised from pCAR ex -VP22 by digestion with HindIII (Klenow fill in) and PmeI and inserted into the SmaI site of pHM3/pBK-CMV. The PI-Sce/I-CeuI fragment of the resulting plasmid was then cloned into the corresponding sites of the adenoviral backbone plasmid pAdHM4, resulting in the plasmid pAdCAR ex -VP22. AdCAR ex -Tat was constructed with the Ad-Easy recombination system according to the manufacturer's instructions (QBiogene). The CAR ex -Tat fragment was isolated from pCAR ex -Tat by HindIII/PmeI digestion and ligated into the HindIII/EcoRV sites of pShuttle-CMV. The resulting vector was linearized with PmeI, and homologous recombination with the adenoviral backbone plasmid AdEasy 1 was performed with BJ5183 Escherichia coli (resulting plasmid, pAdCAR ex -Tat).
For the generation of infectious particles, adenoviral plasmids were linearized with PacI and transfected into permissive 293 cells. After occurrence of a cytopathic effect, cells were harvested and infectious particles were released by three freeze-thaw cycles. Cell debris was removed by centrifugation, and the supernatant was subjected to high-titer preparations. For this purpose, 2 ϫ 10 8 subconfluently grown 293 cells were infected at a multiplicity of infection (MOI) of 5 to 10. Infected cells were harvested when a strong cytopathic effect could be observed, and approximately 50% of the cells were detached. Cells were collected by centrifugation, and viral particles were released by four freeze-thaw cycles. The crude virus suspension was then purified twice by CsCl density gradient centrifugation. Virus preparations were stored at Ϫ20°C in 25% glycerol, 10 mM Tris-HCl (pH 7.4), and 1 mM MgCl 2 . Viral titer was determined by absorbance at an optical density of 260 nm, and the titer of infectious particles was measured by limiting dilution methods or by using the Rapid Titer kit assay (BD Biosciences) according to the manufacturer's instructions.
Construction and generation of the telomerase-dependent replicating adenovirus (hTERT-Ad) was recently described (50) .
Recombinant protein preparation and purification. Limited amounts of recombinant CAR ex -PTD fusion proteins were produced in transfected 293 cells. Cells were transfected by calcium phosphate precipitation with 1 g of expression plasmid for CAR ex fusion proteins, 0.2 g of pCMV-luciferase for deter-mination of transfection efficacy, and 3.8 g of pBluescript (Stratagene). After 36 h, the supernatant of transfected cells was harvested, centrifuged for the removal of detached cells, and subjected to adenovirus infection assays (see below). Luciferase activity was measured in extracts of the cell layer according to standard protocols. The results of the measurements were used to adjust the supernatant application in subsequent infection assays.
Larger quantities of purified recombinant protein were prepared by Ni affinity chromatography. Subconfluent COS-1 cells were infected with AdCAR ex -Tat or AdCAR ex -VP22 at an MOI of 25 in DMEM supplemented with 2% FBS and incubated for 48 h at 37°C and 5% CO 2 . Following incubation, the cells were supplemented with a 1/10 volume of 10ϫ equilibration buffer (500 mM NaH 2 PO 4 , 3 M NaCl, 100 mM imidazol) and incubated for an additional 2 min. After removal of the supernatant, the cells were refed with fresh medium for a further incubation period to increase the yield. Combined supernatants were cleared by centrifugation at 1,000 ϫ g for 10 min and subsequent filtration (0.22-m-pore-size filters), and then subjected to a Ni-nitrilotriacetic acid-agarose (QIAGEN)-containing column equilibrated with 50 mM NaH 2 PO 4 , 300 mM NaCl, and 10 mM imidazol. The column was washed with 50 mM NaH 2 PO 4 , 300 mM NaCl, and 20 mM imidazol and eluted with a buffer containing 50 mM NaH 2 PO 4 , 300 mM NaCl, and 50 mM L-histidine. The concentration of CAR ex -PTD fusion proteins in the eluate was determined by the Bio-Rad protein assay and Sypro-Orange-stained sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Function was controlled by adenoviral infection assays (see below). Eluates were dialyzed against 25% glycerol in DMEM, shock frozen in liquid N 2 , and stored at Ϫ80°C.
Western blot analysis. CAR ex -PTD and control proteins were detected in cell lysates and supernatants from transfected cells by Western blot analysis. To generate whole-cell lysates from transfected cells, the medium was removed and the cells were washed with phosphate-buffered saline (PBS). The cells were harvested in ice-cold RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 0.02% protease inhibitor cocktail in PBS) and resuspended with a syringe (0.8-mm-diameter cannula). After a 60-min incubation on ice, cell debris was pelleted by centrifugation (10,000 ϫ g; 4°C for 5 min), and the supernatant was retained as a whole-cell lysate. For the preparation of freeze-thaw lysates, transfected cells were first washed with PBS and then scraped off in 500 l of PBS per 6-mm dish. The cells were then resuspended by intensive vortexing and subjected to four freeze-thaw cycles in liquid nitrogen. The cell debris was removed as described above. Protein content was measured by using the Bio-Rad protein assay concentrate. Supernatants from transfected cells intended for Western blot analysis were obtained directly from the cell dish, and detached cells were removed by centrifugation (1,000 ϫ g; 5 min). For Western blot analysis, 10 g of protein extract or 20 l of supernatant was separated by SDS-polyacrylamide gel electrophoresis, and proteins were blotted onto a polyvinylidene difluoride membrane (Immobilon; Millipore). CAR ex -PTD or control proteins were detected with a mouse anti-myc antibody (Invitrogen) and a goat horseradish peroxidase-coupled anti-mouse immunoglobulin G antibody (Chemicon). Protein bands were visualized with the Western Lightning Chemiluminescent Reagent Plus according to the manufacturer's protocol (PerkinElmer Life Sciences).
Adenoviral infection assays. The efficacy of adenoviral infection was assessed with a LacZ transgenic adenovirus (AdLacZ, a kind gift from D. Brenner, Chapel Hill, N.C.). Furthermore, an adenoviral vector expressing green fluorescent protein (GFP) (AdGFP, generated by homologous recombination of pTrack-CMV with pAdEasy1) was used for fluorescence microscopy detection or fluorescence-activated cell sorter (FACS) analysis of viral infection. For infection assays, target cells were seeded in 6-cm dishes at a density of 5 ϫ 10 5 cells/dish and grown to subconfluency on the day of infection. The growth medium was removed, and cells were overlaid with infection medium containing CAR ex fusion proteins. For this purpose, either supernatants from transfected 293 cells or affinity-purified protein resolved in fresh DMEM (2% FBS) was applied. When affinity-purified protein was used, protein concentration in these assays was generally 2 nM in a total volume of 3 ml unless otherwise noted in the figure legends. Protein-covered cells were incubated for a further 30 min prior to the addition of AdLacZ or AdGFP resolved in 1 ml of medium. Cells were infected for 30 min to 4 h, and the medium was exchanged to terminate the infection. Cell layers were then incubated for transgene expression for 48 h. Alternatively, purified protein or supernatants were directly added to the virus in a total volume of 4 ml and mixed for 10 min in an overhead shaker prior to the infection of target cells. Following infection, cells were treated as described above. Variations of this protocol or additional treatments are indicated in the figure legends.
To visualize the degree of infection, the cell layer was fixed in ethanol, rehydrated with PBS, and stained with 1 mg of X-Gal substrate (5-bromo-4-chloro-3-indolyl-␤-D-galactoside)/ml, 5 7), respectively. At 4 h after infection, the medium was exchanged, and cells were further incubated until the occurrence of cytopathic effects. Crystal violet staining was used to demonstrate replicationassociated cytopathic effects and subsequent destruction of the cell layer. Six days after infection, the medium was removed, and the cell layer was rinsed with PBS. The wash medium was aspirated, and cells were fixed for 10 min with 10% buffered formaline. Cells were rinsed again with PBS and stained for 30 min with 0.1% crystal violet in 10% ethanol.
RESULTS
PTDs fused to the extracellular domain of CAR facilitate adenoviral infection of nonpermissive carcinoma cells. Expression of the coxsackievirus adenovirus receptor (CAR) on target cell membranes determines susceptibility to adenoviral infection, thus limiting adenovirus-mediated gene transfer. This leads to a restricted access to tumor cells by these vectors, as tumor cells tend to downregulate CAR expression in the course of malignant progression. Since it has been shown that the transmembrane and cytoplasmic domains of CAR are dispensable for adenoviral infection, we hypothesized that fusion proteins consisting of CAR ex and PTDs could overcome the obstacle of insufficient target cell recognition by adenovirus. PTDs are known to attach to cellular membranes independent from a single specific receptor molecule. The usage of adapterlike properties of these molecules should lead to adenoviral target cell binding regardless of the CAR expression status of the respective cell. In initial experiments, we used the entire ectodomain of CAR (aa 1 to 235) to construct fusion proteins with PTDs corresponding to nine arginine residues or natural PTD motifs derived from HIV-Tat and AntP. Also, the whole VP22 protein from HSV was included (see Fig. 1 for a summary of genetic construction). The chosen CAR sequence also contained the natural N-terminal signal sequence (Ld) for proper secretion of recombinant CAR ex -PTD proteins. In the experiments, we also included a construct for testing the effects of Tat-PTD alone on adenoviral infection. This was achieved by deleting large parts of the CAR ex domain of CAR ex -Tat but leaving the CAR signal sequence. Effects on adenoviral infection mediated by VP22 alone were controlled by the commercially available vector expressing VP22. VP22 is known to leave the producer cell, subsequently adhering and transducing neighboring cells. The CAR ex domain linked to 10 Gly/Ser/Thr residues as a nonfunctional PTD was used as an additional negative control (termed CAR ex ) or as competitor in later experiments. Expression and secretion of the constructed proteins were investigated by Western blot analysis ( Fig. 2A ) of whole-cell extracts and supernatants of transfected 293 cells. Though all proteins were correctly expressed as shown by whole-cell extract analysis, CAR ex -9xR and VP22 could not be detected in the supernatant of producer cells (an additional band different from the expected size occurred in VP22 supernatants). There is evidence that a 9-mer of arginine mediates cellular uptake of coupled agents much more efficiently than AntP or Tat (47), suggesting a higher affinity to the respective target structures. Thus, either an improper release and/or efficient rebinding to the producer cells might be considered reasons for the absence of soluble CAR ex -9xR.
To investigate whether application of Tat or chimeric CAR ex -PTD proteins is able to improve viral uptake, we pretreated nonpermissive SKLU-1 and SAOS-2 cells with supernatants of transfected 293 cells. To monitor successful adenoviral infection, an adenovirus encoding LacZ was applied (AdLacZ). Subsequently, efficacy of viral infection was assessed by ␤-galactosidase staining and ␤-galactosidase activity measurements. Treatment of nonpermissive SKLU-1 cells with CAR ex -VP22, CAR ex -Tat, and CAR ex -AntP allowed for efficient adenoviral infection (Fig. 2B) . However, the CAR fusion of AntP was less effective than fusion proteins of Tat and VP22. In contrast to the chimeric CAR ex -PTD proteins, neither CAR ex nor Tat alone improved adenoviral uptake, as these proteins lack either affinity to target cells or the adenoviral particle, respectively (Fig. 2C) . The results could be confirmed with SAOS-2 cells, which possess a low but detectable susceptibility to viral infection. To include putative effects of VP22 and CAR ex -9xR (which are not secreted or improperly secreted), we combined freeze-thaw extracts of producer cells and the corresponding supernatants for pretreatment of the reporter virus (Fig. 2D) . Subsequent infection of HT1080 cells confirmed the efficacy of CAR ex -VP22, CAR ex -Tat and, at least in part, CAR ex -AntP-mediated adenoviral infection, whereas Tat alone had no effect compared to the control (Fig.  2D) . Furthermore, the results revealed an inhibitory effect on adenoviral infection when the CAR ectodomain was applied, showing that this protein can act as a competitor for natural CAR-mediated adenoviral infection. Interestingly, for unknown reasons, the low susceptibility of HT1080 cells was further decreased after the addition of CAR ex -9xR. Together, the results showed that CAR ex -VP22 and CAR ex -Tat represent functional adapter molecules for adenoviral infection. These proteins can be physiologically expressed and obtained in a soluble form, which is an important prerequisite for future in vivo applications. For further studies, we therefore focused on CAR ex -VP22 and CAR ex -Tat proteins and constructed corresponding transgenic adenoviruses for efficient expression and subsequent purification of both fusion proteins. Purified recombinant CAR ex -PTD was then subjected to experiments to assess improvement of viral infection in a large panel of nonpermissive or low-permissive tumor cell lines. The study included rat hepatoma (H4IIE), mouse hepatoma (BNL), mouse skin epidermal (RT-101 and T-36274), human colon carcinoma (RKO), human osteosarcoma (SAOS-2), human lung adenocarcinoma (SKLU-1), human breast carcinoma (MCF-7), and human fibrosarcoma (HT1080) cell lines. In all nonpermissive cancer cells investigated, pretreatment with 2 nM recombinant CAR ex -VP22 and CAR ex -Tat allowed efficient adenoviral infection at low virus titers (Fig. 3A and B) . Adenoviral gene transfer was most enhanced in SKLU-1, BNL, RT-101, and T36274 cells, as these cell lines are completely nonpermissive for untreated virus. Other cell lines tested were at least partially permissive to untreated virus after long-time exposure, suggesting that they can be infected to an acceptable degree when very high virus titers are used. With CAR ex -PTDtreated virus, these cells could be efficiently infected at an MOI of 10. However, as the given cell population was not completely infected under these experimental conditions, we enhanced protein application and virus MOI within a modest range. Figure 3C demonstrates that MCF-7, H4IIE, HT1080, and RKO cells can be almost completely transduced (80 to 100%) using 8 nM adapter protein and AdGFP at an MOI of 30. Together, these results confirmed the broad and effective applicability of CAR ex -PTD-mediated adenoviral gene transfer.
Application of CAR ex -PTDs improves virus uptake rate in permissive carcinoma cell lines. The binding of CAR to the adenoviral fiber knob protein represents a typical receptorligand interaction whose affinity is comparable to CAR-CAR interactions. CAR dimerization is essential for physiological CAR functions as adhesion factor and CAR-CAR binding is disrupted in the presence of fiber knob proteins. As PTDs do not bind to a single specific receptor, it is difficult to estimate their affinity to potential target structures in vivo. Assuming that PTDs have perhaps less affinity to their target structures than fiber knob has to CAR, we considered that CAR ex -PTD binding to adenoviruses might result in reduced infection of permissive tumor cells. Permissive cell lines, including human hepatoma (HepG2 and Huh7), colon carcinoma (HT29), cervix carcinoma (HeLa), osteosarcoma (U2OS), and mouse lung squamous carcinoma (KLN205) cell lines were investigated. Interestingly, a competitive CAR ex -PTD-mediated inhibition of adenoviral infection could not be observed. Moreover, application of CAR ex -VP22 and CAR ex -Tat significantly improved the virus uptake rate in all permissive tumor cells tested when the target cells were exposed to the virus for only a short period of time (Fig. 4) . When the exposure time was prolonged to 4 h, the effect was diminished or disappeared in several cell lines, because transduction efficacy in permissive cells under these conditions is mainly determined by the given MOI. These observations indicate that the broadened tropism of CAR ex -PTD-treated adenovirus does not result in reduction, but in improvement of viral uptake rate in permissive CAR-expressing cells.
Binding of CAR ex -PTD both to adenovirus fiber and to cellular proteoglycans is essential for improvement of adenoviral infection. Our results showed that neither CAR ex nor PTD alone improves uptake of adenovirus in cells. In contrast, CAR ex -PTD improved adenoviral infection efficiently, suggest- ing that CAR ex -PTD indeed functions as a molecular adapter between the adenoviral fiber knob protein and PTD-affinity target structures on cellular membranes. To confirm that specific binding of PTD to adenoviral particles is essential for PTD-mediated viral infection, binding of CAR ex -VP22 and CAR ex -Tat to adenoviral particles was competed for by CAR ex prior to adenoviral infection. Blocking of adenoviral fiber knobs with CAR ex inhibited CAR ex -PTD-mediated adenoviral infection (Fig. 5A) , consistent with our hypothesis that specific binding of PTD to viral particles via the CAR ex domain is important for the improvement of infection.
It has been shown that positively charged PTDs adhere to heparan sulfate-glycosaminoglycans on cell surfaces and that this interaction can be inhibited by negatively charged heparin and soluble heparan sulfate (5) . To investigate the role of CAR ex -PTD protein binding to glycosaminoglycans in PTDmediated viral infection, we treated cells with increasing doses of heparan sulfate or heparin. Heparan sulfate and heparin inhibited CAR ex -VP22-mediated viral infection in a dose dependent manner. CAR ex -Tat-mediated viral infection was also significantly inhibited by heparin but not by heparan sulfate (Fig. 3B) , suggesting differential binding of CAR ex -Tat and CAR ex -VP22 to surface glycosaminoglycans. Taken together, the inhibition of PTD-mediated viral infection by CAR ex and heparin confirms that binding of CAR ex -PTD to adenovirus fiber and to cellular glycosaminoglycans are both essential for CAR ex -PTD-mediated adenoviral infection.
CAR ex -PTD and adenovirus form stable complexes. Competition experiments using CAR ex as described above (Fig. 2D  and 5A ) pointed to a mechanism involving the coating of virus particles by CAR ex -PTD binding to adenoviral fiber knobs. To clarify this issue, we next investigated whether CAR ex -PTD proteins are stably attached to adenoviral particles by binding to fiber knob proteins. Alternatively, we considered that the cell surface is covered by CAR ex -PTDs through PTD-glycosaminoglycan interaction, thus exposing the CAR domain to viral particles. To estimate binding of CAR ex -PTD proteins to cell membranes, SKLU-1 cells were treated with CAR ex -VP22 or CAR ex -Tat for 30 min (Fig. 6A, dish 1) . Subsequently, the supernatant of these cells and subsequent wash fractions were transferred to separate cell dishes, which were then infected with AdLacZ. Only cells that received the supernatant of the initially treated cell layer showed an enhanced susceptibility for adenoviral infection, suggesting low binding strength of CAR ex -PTD to cell surfaces. Like cells from dish 1 (Fig. 6A) , both cell layers treated with the wash fractions did not show any adenoviral infection, indicating that CAR ex -PTD proteins were almost completely removed simply by transferring the supernatant.
To investigate the stability of CAR ex -PTD attachment to adenoviral fiber knobs, AdGFP was treated with purified recombinant CAR ex -VP22 or CAR ex -Tat in a 10-fold molar excess regarding the fiber knob molecules. To separate unbound proteins from viral particles, the adenovirus preparations were subjected to a CsCl density gradient ultracentrifugation. CAR ex -PTD-treated adenoviruses still infected nonpermissive tumor cells effectively, even after a density gradient ultracentrifugation (Fig. 6C) , indicating the formation of stable complexes of adenoviral particles with CAR ex -PTDs. As a consequence of these observations together with the competition results described above, we concluded that the molecular mechanism of CAR ex -PTD-mediated viral infection preferably involves stable complexing of viral particles with CAR ex -PTDs prior to cell surface binding, rather than CAR ex -PTD coating of cell surfaces prior to recognition by adenoviral particles.
CAR ex -VP22 is more stable than CAR ex -Tat. Recombinant CAR ex -PTD proteins might serve as effective agents to improve adenoviral infection and to broaden the application spectrum of adenoviral vectors. For wide applicability, the stability of protein isolates is an important requirement. We therefore investigated stability of CAR ex -PTD by treating protein isolates with repeated freeze-thaw cycles. As shown in Fig.  7 , both CAR ex -PTD proteins retained most of their capability to improve adenoviral infection following at least four freezethaw cycles. However, the activity of CAR ex -Tat was largely destroyed after six freeze-thaw cycles, whereas CAR ex -VP22 was almost stable. Consistent with these findings, CAR ex -VP22 was also more resistant to heat than CAR ex -Tat (data not shown). (16, 51) , dendritic cells (22, 30, 33) , or neuronal cells (31) . As nonepithelial cells express little or no CAR, an acceptable degree of viral infection usually requires very high adenovirus doses, which often impair target cell specific functions and/or result in cytopathic effects due to fiber knob-related toxicity. Therefore, we investigated the utility of CAR ex -PTD proteins for improvement of adenoviral infection of cell lines representing macrophages, Schwann cells, and dendritic cells. As shown in Fig. 8A , CAR ex -Tat and CAR ex -VP22 strongly improved adenoviral uptake at a low MOI in RAW264.7 and P388 D.1 cells. These cell types could be almost completely transduced with an MOI of 30 and 8 nM recombinant CAR ex -PTD (Fig. 8B) . CAR ex -PTD application improved transduction of DC2.4 dendritic cells (Fig. 8C) and Jurkat T-cells (data not shown). Furthermore, CAR ex -PTD-mediated adenoviral infection was highly effective in rat immortalized Schwann cells (Fig. 8D) . The results underline that CAR ex -PTD proteins are valuable tools for efficient and nontoxic adenoviral gene transfer in a large variety of cell types.
Receptor-independent infection by CAR ex -PTD enhances lysis of tumor cells by conditionally replicating vectors. Virotherapy of solid tumors is often impaired by the lack of virus spreading in virus-receptor negative tumors. Several attempts have been made to enhance the oncolytic activity of conditionally replicating viruses by retargeting of vectors to tumor-specific receptors, such as epidermal growth factor receptor. However, receptor-mediated infection is a general limitation of virotherapy because of the heterogeneity of receptor expression in human tumors. The accelerated receptor-independent viral infection by CAR ex -PTDs may be a potential tool to overcome a major bottleneck in the field of oncolytic virotherapy, namely the lack of efficient viral spreading caused by barriers of receptor-negative tumor cells. To investigate whether physiological expression of CAR ex -PTD is suitable to improve infection and viral spreading of replicating adenoviruses, we treated tumor cells with Ad-wt or with hTERT-Ad. Expression of CAR ex -PTDs by nonreplicating adenoviruses facilitated efficient lysis of nonpermissive tumor cells (Fig. 9A) . The same results were obtained when the CAR ex -PTD-expressing and control viruses were precoated with purified CAR ex -VP22 (in a 10-fold molar excess according to the fiber knob) and when the viruses were subsequently applied at a lowered MOI of 2 (data not shown). This procedure should exclude the possibility that the results can be attributed to a CAR ex -PTDmediated changing of the effective MOI of the initial infection.
Additionally, CAR ex -PTD-mediated viral infection enhanced the oncolytic activity of hTERT-Ad and Ad-wt in permissive tumor cells as well, indicating an improved uptake of vectors mediated by CAR ex -PTDs compared to CAR-receptor-mediated infection (Fig. 9B) .
DISCUSSION
Viral infection requires binding of viral particles to the plasma membrane. As a consequence, expression of viral receptors determines viral tropism and frequently limits effective gene delivery by viral vectors. It has recently been shown that application of small synthetic Tat-and AntP-PTD peptides may increase viral entry and that these molecules could improve gene expression at reduced viral titers to circumvent cytotoxicity (18) . Regarding our physiological experimental conditions, only PTDs fused to the viral receptor domain CAR ex , which facilitated adenoviral infection of nonpermissive cells at low titers. There was no evidence for an infectionimproving effect mediated by Tat-PTD alone, indicating that specific binding of the PTD to the viral particle via the CAR ex domain is necessary for efficient PTD-mediated viral infection. However, the discrepancy of results may be explained by different experimental conditions. Whereas Gratton et al. (18) preincubated adenoviral particles with up to 0.5 mM synthetic AntP-PTD or Tat-PTD peptides, we used either supernatants containing physiologically expressed CAR ex -Tat or purified CAR ex -Tat at concentrations of 2 nM to obtain significant effects. Assuming that the protein in our preparations was fully active, the concentrations differed by a calculated factor of 2.5 ϫ 10 5 fold, comparing both approaches. This underlines the efficacy and physiological relevance of CAR ex -PTD application for adenoviral gene transfer. The importance of PTD binding to viral particles via CAR ex was further confirmed by blocking of adenoviral fiber knobs through CAR ex , which resulted in a dose-dependent competitive inhibition of CAR ex -PTD-mediated adenoviral infection. Furthermore, we were able to stably complex adenoviral particles with CAR ex -PTDs. CAR ex -PTD binding to adenoviral particles was resistant to density gradient ultracentrifugation. As we found no evidence of strong binding of CAR ex -PTDs to cellular surfaces, we postulate a mechanism for CAR ex -PTD-mediated adenoviral infection including CAR ex -PTD covering of the viral fiber knobs, subsequently leading to cell surface attachment via PTD. However, the exact mechanisms of subsequent particle internalization following CAR ex -PTD-mediated cell surface recognition have to be elucidated and await future experiments. Primarily, the role of integrins is of significant interest. Furthermore, CAR ex -PTDmediated adenoviral infection can serve as a suitable experimental model to identify and characterize further target structures for HIV Tat and HSV VP22.
Since many cancer cells downregulate CAR expression, several attempts have been made to retarget adenoviral vectors to tumors to achieve effective infection. To overcome low affinity of adenoviral vectors to CAR-negative tumor cells, bispecific antibodies or fusion proteins which bind the adenoviral fiber knob and target receptors overrepresented on tumor cell surfaces, such as epidermal growth factor receptor, have been used to mediate viral attachment and infection (6, 10, 12, 20, 32) . Another strategy to enhance the affinity of adenoviruses to cells includes mutations of the fiber knob by inserting arginineglycine-aspartic acid (RGD)-charged or negatively charged polylysine motifs (49) . However, incorporating mutations into the fiber knob can depress fiber protein synthesis, which results in significantly decreased viral titers and impaired viral spreading within a tumor tissue.
Our results showed that receptor-specific targeting is not essential for efficient viral infection. PTDs linked to viral particles sufficiently mediate viral infection in all nonpermissive cells investigated. Additionally, CAR ex -PTD application significantly enhances viral uptake in permissive cancer cells, demonstrating that CAR ex -PTD-mediated infection is equivalent to or, under certain conditions, even more effective than receptor-specific viral uptake. Retargeting of viral vectors to receptors overexpressed by tumors may lead to a reduction of undesirable side effects in vivo but may also strongly limit the efficacy of gene delivery, considering heterogeneous receptor expression of tumor subpopulations within tumor entities. Tumor-restricted replication of viral vectors combined with CAR ex -PTD-mediated spreading of the replicating vectors within tumor tissue may be a solution to this dilemma. We therefore investigated whether expression of CAR ex -PTD improves the oncolytic activity of a telomerase-dependent conditionally replicating adenovirus. Interestingly, PTD-mediated viral infection enhanced not only oncolysis of nonpermissive tumor cells but also highly permissive cancer cells, indicating that receptor-independent infection by PTD is an attractive strategy for virotherapy of tumors. The CAR ex -PTD-mediated adenoviral infection retargets the virus to nonspecific cell surface structures also abundant on normal cells. Hypothetically, this could raise safety and toxicity problems, which certainly have to be addressed in future in vivo experiments. However, if CAR ex -PTD is encoded by a tumor-specific conditionally replicating virus (such as hTERT-Ad), high concentrations of extracellular CAR ex -PTD should be restricted to regions where the virus productively replicates.
Gene transfer with adenoviral vectors in nonepithelial cells, such as T cells (34) , macrophages (16, 51) , or dendritic cells (22, 30, 33) , has been reported. However, high virus doses and prolonged exposure of target cells to virus were required, and cytopathic effects and changes of the target cell properties are considerable shortcomings of this approach. In contrast, CAR ex -PTDs facilitate efficient adenoviral infection at low titers and short exposure times, avoiding vector-related toxicity. Since there was no evidence of cytotoxicity of recombinant CAR ex -PTD fusion proteins in our experiments ( 
